The Manufacturers Life Insurance Company Increases Stock Position in Artivion, Inc. (NYSE:AORT)

The Manufacturers Life Insurance Company lifted its holdings in shares of Artivion, Inc. (NYSE:AORT) by 3.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 15,301 shares of the company’s stock after purchasing an additional 481 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Artivion were worth $392,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Artivion by 1.3% during the first quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock worth $56,388,000 after purchasing an additional 33,982 shares in the last quarter. Wasatch Advisors LP lifted its position in shares of Artivion by 108.8% during the first quarter. Wasatch Advisors LP now owns 1,083,568 shares of the company’s stock worth $22,928,000 after purchasing an additional 564,549 shares in the last quarter. First Eagle Investment Management LLC lifted its position in shares of Artivion by 4.9% during the second quarter. First Eagle Investment Management LLC now owns 598,148 shares of the company’s stock worth $15,342,000 after purchasing an additional 27,906 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Artivion by 0.7% during the second quarter. Bank of New York Mellon Corp now owns 301,992 shares of the company’s stock worth $7,746,000 after purchasing an additional 2,018 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in Artivion by 5.0% in the first quarter. Principal Financial Group Inc. now owns 220,445 shares of the company’s stock valued at $4,665,000 after acquiring an additional 10,479 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Insiders Place Their Bets

In other Artivion news, CAO Amy Horton sold 12,430 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the transaction, the chief accounting officer now directly owns 139,989 shares of the company’s stock, valued at $3,664,912.02. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Artivion news, VP Matthew A. Getz sold 9,420 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $25.31, for a total value of $238,420.20. Following the sale, the vice president now directly owns 34,116 shares of the company’s stock, valued at $863,475.96. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Amy Horton sold 12,430 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the completion of the sale, the chief accounting officer now directly owns 139,989 shares in the company, valued at $3,664,912.02. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 37,109 shares of company stock worth $951,935 in the last 90 days. 8.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

AORT has been the topic of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 target price on shares of Artivion in a report on Friday, September 27th. Oppenheimer lifted their price objective on shares of Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Stifel Nicolaus boosted their target price on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, September 13th. Finally, Lake Street Capital lifted their price target on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, July 2nd.

Artivion Trading Up 1.8 %

Shares of AORT stock opened at $26.89 on Thursday. The company has a current ratio of 5.63, a quick ratio of 4.04 and a debt-to-equity ratio of 1.07. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -112.04 and a beta of 1.74. The firm has a 50-day moving average price of $25.66 and a 200 day moving average price of $24.40. Artivion, Inc. has a twelve month low of $12.16 and a twelve month high of $29.24.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, August 8th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.04. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. The business had revenue of $98.02 million during the quarter, compared to analysts’ expectations of $97.70 million. Research analysts forecast that Artivion, Inc. will post 0.2 earnings per share for the current fiscal year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.